50 E. Hamilton Avenue
Suite 200
Campbell, CA 95008
Phone: 408-376-2300
Fax: 408-376-2316
Southbay Oncology Hematology Partners
Personalized treatment with expert professional care in a supportive environment
Clinical Trials
Marta Roeder, R.N., B.S.N, O.C.N. is the administrative director of the SBOHP clinical trials program and the Nursing Manager for the practice. An oncology certified nurse, Marta joined Southbay Oncology Hematology Partners in 1991 and has conducted over twenty clinical studies. Prior to joining SBOHP, Marta worked for 10 years as a Pediatric Oncology nurse. She received her Associate degree in Nursing at Goldenwest College and her Baccalaureate degree in Nursing at California State Long Beach. Marta has over 25 years of oncology experience.
When not at work, Marta enjoys spending time with her husband and three teenage children, accompanying them to their various sporting, scouting and church events. She also enjoys gardening, cooking and home improvement projects.
Please contact Marta at 408-376-2310 or at marta@sbohp.com with any questions regarding clinical research provided at Southbay Oncology Hematology Partners.
Open Clinical Studies
LUNG CANCER
-
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.
For more information about this study, please call Marta at 408-376-2310 or visit the website, by clicking here.
BREAST CANCER
- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)
Rationale: For women with early-stage breast cancer, bone is a frequent site of relapse, and most women with advanced breast cancer will eventually develop disease in the bone.
Denosumab, a fully human monoclonal antibody that specifically inhibits RANK ligand, may have the potential to interrupt the hypothetical "vicious cycle" of cancer-induced bone destruction and tumor cell expansion through the bone. It is not yet known if denosumab may prevent disease recurrence in the bone or in any other part of the body.
Purpose: This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast cancer, who are at high risk of disease recurrence.
For more information about this study, please call Marta at 408-376-2310 or visit the website, by clicking here.
- A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or metastatic breast cancer who have not received chemotherapy or have received one non-taxane based chemotherapy for metastatic breast cancer.
For more information about this study, please call Marta at 408-376-2310 or visit the website, by clicking here.
Contact Us
We appreciate your continuing support of Southbay Oncology Hematology Partners.
Please call us at 408-376-2300 during normal office hours or email us at contact@sbohp.com for non-urgent medical matters. Please do not email personal health information as the network connection you are using may not be secure.